Stock Events

Stock Events

Nanexa AB 

0
0
+SEK0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

27AugExpected
Q2 2025
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-31.5%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
36.15MRevenue
-11.39MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. develops advanced drug delivery systems and pharmaceuticals, competing in the same sector as Nanexa.
Novartis
NVS
Mkt Cap286.78B
Novartis AG focuses on innovative pharmaceutical solutions, including drug delivery technologies similar to Nanexa's.
Pfizer
PFE
Mkt Cap152.69B
Pfizer Inc. is involved in developing advanced drug delivery systems which align with Nanexa's business model.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson operates in the pharmaceutical and biotechnology field, directly competing with Nanexa in drug delivery solutions.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie Inc. works on novel pharmaceutical formulations, competing with Nanexa in the drug delivery space.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company develops pharmaceutical products that often incorporate advanced drug delivery technologies.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol-Myers Squibb Company offers pharmaceutical products that compete with Nanexa's drug delivery technologies.
GSK
GSK
Mkt Cap99.18B
GlaxoSmithKline plc engages in the creation of drug delivery systems, which pits them against Nanexa.
Sanofi
SNY
Mkt Cap104.76B
Sanofi operates globally in pharmaceuticals, including drug delivery systems that compete with Nanexa's technologies.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca PLC specializes in biopharmaceuticals, including drug delivery systems that rival Nanexa's products.

About

Nanexa AB (publ) is a firm dedicated to developing advanced drug delivery solutions through nanotechnology. The company leverages its proprietary PharmaShell platform, a nanobased system that utilizes atomic layer deposition (ALD) technology for drug administration. Furthermore, Nanexa is progressing NEX-18, a PharmaShell-based candidate specifically designed to address severe conditions such as Myelodysplastic Syndrome and Acute Myeloid Leukemia. The company was established in 2007 and is headquartered in Uppsala, Sweden.
Show more...
CEO
David Westberg
Employees
16
Country
Sweden
ISIN
SE0020997500

Listings

ST
SE
NANEXA-BTA.ST
ST
SE
NANEXA.ST
F
DE
40M.F

0 Comments

Share your thoughts

FAQ

What is Nanexa AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange Nanexa AB stocks are traded under the ticker NANEXA-BTA.ST.
What is Nanexa AB revenue for the last year?▼
Nanexa AB revenue for the last year amounts to 36.15M SEK.
What is Nanexa AB net income for the last year?▼
NANEXA-BTA.ST net income for the last year is -11.39M SEK.
How many employees does Nanexa AB have?▼
As of August 23, 2026, the company has 16 employees.
In which sector is Nanexa AB located?▼
Nanexa AB operates in the Health & Wellness sector.
When did Nanexa AB complete a stock split?▼
Nanexa AB has not had any recent stock splits.
Where is Nanexa AB headquartered?▼
Nanexa AB is headquartered in Uppsala, Sweden.